



Ferric Sulfate in Dentistry – A Review

R Mithun Desikan ^a, Joyson Moses ^b, Sharanya, L ^c

^a Intern, ^b Professor, Head of Department, ^c Professor, Department of Pedodontics and Preventive Dentistry, Thai Moogambigai Dental College and Hospital, Mogappair, Chennai – 600 107.

ABSTRACT:

Ferric sulfate ($\text{Fe}_2(\text{SO}_4)_3$) is a widely used coagulant and local hemostatic agent in dentistry that was first used in medicine in 1950's. It is used in a variety of fields including dermatology and dentistry, and it is thought to have hemostatic properties due to chemical interactions with blood proteins. FS has gained widespread acceptance as a pulpotomy medicament in modern dentistry; however, it has several applications in other fields of dentistry that have received little attention. As a result, the goal of this review is to explore the various applications of FS in dentistry.

KEYWORDS: Ferric sulfate, haemostatic agent, bleeding, haemostasis, dentistry.

INTRODUCTION:

Controlling haemorrhage is essential in dental procedures for good field visualisation. Dentists perform a wide range of operative procedures, including pulpotomy, tooth extraction, biopsies, endosseous implant placement, periradicular and periodontal surgery, all of which may necessitate haemorrhage control [1,2]. The most common method for controlling bleeding is to apply mechanical pressure to the wound surface. When cotton balls or gauze pads are used, fibres may be left in the surgical site. These fibres may cause a foreign body reaction and cause healing to be delayed [3]. The use of hemostatic agents is another method for controlling bleeding [4]. In dentistry, various agents such as ferric sulphate and Ankaferd Blood Stopper (ABS) are used to control haemorrhage. Ferric sulphate, denoted as FS [$\text{Fe}_2(\text{SO}_4)_3$], is a trivalent iron sulphate (Iron (3+) sulphate is a compound of iron and sulphate with a 3:2 iron (3+) to sulphate ion ratio). It has a rhombic crystalline salt, is dark brown or yellow in colour, and is soluble in water at room temperature. It is created by combining sulfuric acid, a hot solution of ferrous sulphate, and an oxidising agent. In the field of dermatology, it was first used as Monsel's solution in 1856 [5]. Blood protein agglutination is thought to be caused by the reaction of blood with ferric and sulphate ions. Thus, the capillary orifices have been obturate by bonded proteins [6].

CHEMICAL FORMS:

There are two chemical forms of ferric sulphate available:

Ferric subsulfate [$\text{Fe}_4(\text{OH})_2(\text{SO}_4)_3$] (Monsel's solution)

Monsel's solution (20% FS) is an effective styptic agent in skin and mucosal biopsies [5,7,8]. However, the ferric and ferrous salts are corrosive and harmful to both soft and hard tissues, causing subsequent tooth staining due to their high acidity (72%, $\text{pH} < 1$) [7]. Postoperative soft tissue complications include delayed reepithelialization and dyspigmentation [9]. It also has a reactive and degenerative effect [5,10]. At 4 weeks, Armstrong et al. observed inflammation, a higher incidence of wound infection, and a delayed reepithelialization rate in punch biopsy wounds treated with Monsel's solution versus collagen matrix [11].

Ferric sulfate [$\text{Fe}_2(\text{SO}_4)_3$]

FS is a coagulative and haemostatic agent in a 15.5% solution that forms a ferric ion-protein complex when it comes into contact with blood. It mechanically seals the damaged vessels, resulting in haemostasis, and the agglutinated protein complex occludes the capillary orifices, preventing blood clot formation [5]. It causes a reversible local inflammatory response in the oral soft tissues [12]. Because of its quick action, the recommended application time is 1-3 minutes, and it should be placed directly against the damaged tissue. Above 15% FS solutions are highly acidic and may cause significant tissue irritation and postoperative root sensitivity.

MERITS OF FERRIC SULFATE:

- Adequate hemostasis
- Saving chair time
- Less time consuming
- Cost effective
- Effective and simple to use for control of bleeding, tissue management, and pulpotomies [7,9,11].

APPLICATION OF FERRIC SULFATE IN DENTISTRY:

As an Antimicrobial agent:

Ferric sulfate not only has hemostatic properties, but it also has antimicrobial properties. Under in vitro conditions, the antibacterial efficacy of ferric sulfate is comparable to 0.2% chlorhexidine digluconate but superior to Ankaferd blood stopper® against oral microorganisms such as *Staphylococcus aureus*, *Enterococcus faecalis*, *Candida albicans*, *Porphyromonas gingivalis*, *Lactobacillus acidophilus*, *Lactobacillus salivarius*, *Streptococcus mutans* [16]. This could be because of its acidic pH4 and cytotoxicity [3]. Furthermore, the occlusion of capillary orifices by agglutinated proteins prevents bacterial ingress [16].

In paediatric dentistry:

In the last three decades, ferric sulfate has been widely used as a pulpotomy medicament to control pulpal bleeding in vital pulp therapy. It induces hemostasis by agglutinating blood proteins with ferric and sulfate ions and forming a sealing membrane at the damaged vessels of pulpal tissue [13]. The nonaldehyde form of ferric sulphate is preferred as a pulpotomy agent due to its haemorrhage-control mechanism, which is thought to be associated with physiological clot formation. When placed on the amputated pulp tissue for 5 minutes, this may reduce the chances of inflammation and internal resorption [17]. The most common type of ferric sulfate is minimal devitalization and pulp tissue preservation [13]. Because of physiological clot formation by the agglutinated proteins, ferric sulfate outperformed calcium hydroxide in terms of minimising inflammation and internal resorption [3,17].

Landau and Johnsen described using ferric sulfate as a pulpotomy medicament in monkey teeth [19]. With a 1-year follow-up, Fei et al. published the first human clinical trial using ferric sulfate with 100% clinical success compared to formocresol (77%) [13]. Ibricevic et al. described that ferric sulphate showed similar clinical and radiographic success rate as a pulpotomy agent for primary molar teeth after long term evaluation period, compared with formocresol. Ferric sulphate, because of its lower toxicity, may become a replacement for formocresol in primary molar teeth [41].

Fucks er al. demonstrated that ferric sulfate performed better when compared to formocresol in the pulpotomy of carious deciduous teeth, however without reporting statistically significant differences. Specifically, after 12 months, a total success rate of 92.7% and 83.8% was reported [42] and a clinical success rate of 96.7% and 86.7% was reported by Havale et al. in primary molars that underwent pulpotomy with ferric sulfate and formocresol, respectively [18]. Ozmen et al. compared three pulpotomy agents, such as formocresol, ferric sulfate and Ankaferd blood stopper (ABS), and reported a more favorable clinical success rate for FS (100%) than other evaluated materials (87% for both ABS and formocresol) after a follow-up of 24 months [43].

In restorative dentistry:

Ferric sulfate in concentrations ranging from 15.5% to 20% is one of the most commonly used chemical hemostatic reagents in restorative dentistry [20,21,22]. It is chemically impregnated into retraction cords in the chemomechanical gingival retraction technique, in which ferric sulfate is used at a concentration of 15%-25% for 3-10 minutes, and it provides greater sulcus displacement due to the combined physical and chemical effect [20,23].

Conrad and Holtan discovered that using ferric sulfate gingival retraction fluid in conjunction with translucent porcelain restorations resulted in black internal discoloration of the dentin beneath porcelain crowns [15]. Dentinal exposure to such highly acidic FS solutions (pH range of 0.7-2.0) for 30 seconds results in rapid removal of the superficial smear layer, and peritubular dentin was also lost after prolonged exposure [24]. Furthermore, removal of the smear layer by hemostatic agents has been shown to have a negative effect on the bonding mechanism of self-etching adhesive, which may promote marginal microleakage and discoloration [15,25,14]. As a result, cavity disinfection-associated resin composite restorations are material specific [26]. Cohesive failures were observed in primary dentin bonded with self-etch adhesive systems following the application of FS [27].

Ebrahimi et al. discovered that contaminating dentin surfaces with ViscoStat® for 60 seconds before applying adhesives reduced the shear bond strength of the adhesive to the dentin. The majority of the observed failures were adhesive [28]. To achieve better results during impression making or bonding agent application, the hemostatic agents used before or during etching should be thoroughly rinsed away to create a dentin smear layer. However, rinsing alone cannot remove surface contamination, and thus the residual FS interfered with adhesive diffusion in dentinal tubules [28,29]. Because of the weak acidity of the primer in self-etch adhesives, they were unable to dissolve the contamination by ViscoStat®; thus, deeper penetration into dentin is impossible [29]. The proposed mechanism was that hemostatic agents cause bonding procedure derangement due to dentinal tubule obturation and dentinal

surface demineralization at different values [14]. It is strongly advised that FS be used only with etch-and-rinse adhesive systems. [23] When compared to normal dentin, the use of self-etching adhesive significantly reduced the bond strength of dentin contaminated with the hemostatic agent. Kuphasuck et al. discovered that the hemostatic agent has no effect on the total-etching adhesive's dentin bond strength [14].

In prosthodontics:

Ferric sulfate was first used as a coagulative and haemostatic agent during crown and bridge impressions by Fischer (1987) [7]. It is used for tissue displacement and is kept on for at least 30 minutes. [7,30] Nonetheless, its use in implantology for gingival displacement is unclear due to its ability to disrupt the setting reaction of polyether and polyvinyl siloxane impression materials [15,31]. Because of its iron content, FS stains gingival tissue yellow-brown to black for several days after application. It has been demonstrated that it interferes with the surface details of impression materials and discolours dentin by precipitating ferric sulphide in an anaerobic environment [15]. Irrigating gingiva and aesthetic restorations with water for at least 10 seconds removes the staining and discoloration effect of ferric compounds. Furthermore, two studies found that the surfactant effect of chlorhexidine gluconate helps achieve haemostasis in less time [31,32]. After applying ferric sulfate, Shaw et al. observed reversible damage to the connective tissue adjacent to the sulcular gingiva [34]. Nonetheless, when used for 10 minutes in the gingival sulcus, they cause minimal tissue damage [20,21,22].

In periradicular and endodontic surgery:

Controlling bleeding during any surgical procedure is essential, and this can be accomplished through practical and effective systemic or topical approaches. When applied in the bony crypt under light pressure, epinephrine pellets, either alone or in combination with a ferric sulfate-soaked pellet, are effective topical hemostats [34]. Aluminum chloride, either alone or in combination with ferric sulfate (Stasis®), appeared to be the most effective hemostatic agent for periapical bleeding control [35,36]. Vickers et al. reported that in one-third of the cases where ferric sulfate was used, some oozing of blood occurred in the bony crypt, necessitating suction to keep the root-end preparation dry [37]. However, ferric sulfate was found to be less effective than aluminium chloride in controlling bleeding. Kim and Kratchman suggested using FS only on small bleeding points on the cortical bone surface [38]. When ferric sulfate was left in place for maximum exposure, an intense inflammatory response including foreign body reaction and delayed osseous healing was documented histologically after 18 and 46 days [3]. However, when the surgical site is adequately curetted and irrigated before closure, ferric sulfate does not cause persistent inflammation or delay osseous repair [39]. Adequate hemostasis can be achieved by applying 20% ferric sulfate (Viscostat®) for 5 seconds during endodontic surgeries such as root-end resection, root-end preparation, and root-end filling [37].

For post extraction haemorrhage:

Although FS is not widely used to control post-extraction haemorrhage, it may help with mucosal tears or uncontrolled post-extraction haemorrhage in gingival tissues [40].

DEMERITS OF FERRIC SULFATE:

- Tissue discoloration
- Acidic in taste
- Adhesive bond strength reduction
- Risk sulcus contamination
- Causes microleakage under restoration [13,14,15].

CONCLUSION:

When compared to other chemical hemostatic agents, the Ferric sulfate has been equally effective as a local hemostatic agent. Ferric sulfate is a common astringent solution (15.5%) with numerous applications in dentistry. It is widely used as a hemostatic agent in dentistry. Its use in restorative and endodontic dentistry, paediatric dentistry, prosthodontics, and oral surgery is not well documented. As a result, more research into the effective application of Ferric sulfate in various fields of dentistry is required.

REFERENCES:

1. McBee WL, Koerner KR. Review of hemostatic agents used in dentistry. *Dent Today*. 2005;24:62–5.
2. Baykul T, Alanoglu EG, Kocer G. Use of Ankaferd Blood Stopper as a hemostatic agent: a clinical experience. *J Contemp Dent Pract*. 2010;11:E088–94.
3. Lemon RR, Steele PJ, Jeanson BG. Ferric sulfate hemostasis: effect on osseous wound healing. Left in situ for maximum exposure. *J Endod*. 1993;19:170–3.

4. Odabas ME, Erturk M, Cinar C, Tuzuner T, Tulunoglu O. Cytotoxicity of a new hemostatic agent on human pulp fibroblasts in vitro. *Med Oral Patol Oral Cir Bucal*. 2011;16:e584-7.
5. Epstein E, Maibach HI. Monsel's solution; history, chemistry, and efficacy. *Arch Dermatol*. 1964;90:226-8.
6. Bandi, M., Mallineni, S. K., & Nuvvula, S. (2017). Clinical applications of ferric sulfate in dentistry: A narrative review. *Journal of conservative dentistry : JCD*, 20(4), 278-281. https://doi.org/10.4103/JCD.JCD_259_16.
7. Fischer DE. Tissue management: A new solution to an old problem. *Gen Dent*. 1987;35:178-82.
8. Larson PO. Topical hemostatic agents for dermatologic surgery. *J Dermatol Surg Oncol*. 1988;14:623-32.
9. Amazon K, Robinson MJ, Rywlin AM. Ferrugination caused by Monsel's solution. Clinical observations and experimentations.
10. Olmstead PM, Lund HZ, Leonard DD. Monsel's solution: A histologic nuisance. *J Am Acad Dermatol*. 1980;3:492-8.
11. Armstrong RB, Nichols J, Pachance J. Punch biopsy wounds treated with monsel's solution or a collagen matrix. A comparison of healing. *Arch Dermatol*. 1986;122:546-9.
12. Casas MJ, Kenny DJ, Johnston DH, Judd PL. Long-term outcomes of primary molar ferric sulfate pulpotomy and root canal therapy. *Pediatr Dent*. 2004;26:44-8.
13. Fei AL, Udin RD, Johnson R. A clinical study of ferric sulfate as a pulpotomy agent in primary teeth. *Pediatr Dent*. 1991;13:327-32.
14. Kuphasuck W, Harnirattisai C, Senawongse P, Tagami J. Bond strength of two adhesive systems to dentin contaminated with a hemostatic agent. *Oper Dent*. 2007;32:399-405.
15. Conrad HJ, Holtan JR. Internalized discoloration of dentin under porcelain crowns: A clinical report. *J Prosthet Dent*. 2009;101:153-7.
16. Cinar C, Odabaş ME, Akca G, Işık B. Antibacterial effect of a new haemostatic agent on oral microorganisms. *J Clin Exp Dent*. 2012;4:e151-5.
17. Schröder U. Effect of an extra-pulpal blood clot on healing following experimental pulpotomy and capping with calcium hydroxide. *Odontol Revy*. 1973;24:257-68.
18. Havale R, Anegundi RT, Indushekar K, Sudha P. Clinical and radiographic evaluation of pulpotomies in primary molars with formocresol, glutaraldehyde and ferric sulphate. *Oral Health Dent Manag*. 2013;12:24-31.
19. Landau MJ, Johnsen DC. Pulpal responses to ferric sulfate in monkeys. *J Dent Res*. 1988;67:215.
20. Rosenstiel SF. Tissue management and impression making. In: Rosenstiel SF, Land M, Fujimoto J, editors. *Contemporary Fixed Prosthodontics*. 4th ed. St. Louis, MO: Mosby-Elsevier; 2006. pp. 431-65.
21. Morgano SM, Malone WF, Gregoire SE, Goldenberg BS. Tissue management with dental impression materials. *Am J Dent*. 1989;2:279-84.
22. Akca EA, Yildirim E, Dalkiz M, Yavuzylmaz H, Beydemir B. Effects of different retraction medicaments on gingival tissue. *Quintessence Int*. 2006;37:53-9.
23. Tarighi P, Khoroushi M. A review on common chemical hemostatic agents in restorative dentistry. *Dent Res J (Isfahan)* 2014;11:423-8.
24. Land MF, Rosenstiel SF, Sandrik JL. Disturbance of the dentinal smear layer by acidic hemostatic agents. *J Prosthet Dent*. 1994;72:4-7.
25. O'Keefe KL, Pinzon LM, Rivera B, Powers JM. Bond strength of composite to astringent-contaminated dentin using self-etching adhesives. *Am J Dent*. 2005;18:168-72.
26. Sharma V, Nainan MT, Shivanna V. The effect of cavity disinfectants on the sealing ability of dentin bonding system: An *in vitro* study. *J Conserv Dent*. 2009;12:109-13.
27. Prabhakar AR, Bedi S. Effect of glutaraldehyde and ferric sulfate on shear bond strength of adhesives to primary dentin. *J Indian Soc Pedod Prev Dent*. 2008;26(Suppl 3):S109-13
28. Ebrahimi SF, Shadman N, Abrishami A. Effect of ferric sulfate contamination on the bonding effectiveness of etch-and-rinse and self-etch adhesives to superficial dentin. *J Conserv Dent*. 2013;16:126-30.
29. Harnirattisai C, Kuphasuk W, Senawongse P, Tagami J. Bond strengths of resin cements to astringent-contaminated dentin. *Oper Dent*. 2009;34:415-22.
30. Christensen GJ, Christensen R. Astringedent by ultradent. *Clin Res Assoc Newsletter*. 1979;3:2.
31. Prasad KD, Hegde C, Agrawal G, Shetty M. Gingival displacement in prosthodontics: A critical review of existing methods. *J Interdis Dent*. 2011;1:80-6.

32. Wassell RW, Barker D, Walls AW. Crowns and other extracoronal restorations: Impression materials and technique. *Br Dent J.* 2002;192:679.
33. Shaw DH, Krejci RF, Kalkwarf KL, Wentz FM. Gingival response to retraction by ferric sulfate (Astringedent) *Oper Dent.* 1983;8:142-7.
34. Jang Y, Kim H, Roh BD, Kim E. Biologic response of local hemostatic agents used in endodontic microsurgery. *Restor Dent Endod.* 2014;39:79-88.
35. Maestre-Ferrin L, Penarrocha-Diago M. Hemostatic agents used in apical surgery: A review. *J Clin Exp Dent.* 2011;3:e310-3.
36. von Arx T, Jensen SS, Hänni S, Schenk RK. Haemostatic agents used in periradicular surgery: An experimental study of their efficacy and tissue reactions. *Int Endod J.* 2006;39:800-8.
37. Vickers FJ, Baumgartner JC, Marshall G. Hemostatic efficacy and cardiovascular effects of agents used during endodontic surgery. *J Endod.* 2002;28:322-3.
38. Kim S, Kratchman S. Modern endodontic surgery concepts and practice: A review. *J Endod.* 2006;32:601-23
39. Jeansonne BG, Boggs WS, Lemon RR. Ferric sulfate hemostasis: Effect on osseous wound healing. II. With curettage and irrigation. *J Endod.* 1993;19:174-6.
40. McCormick NJ, Moore UJ, Meechan JG. Haemostasis. Part 1: The management of post-extraction haemorrhage. *Dent Update.* 2014;41:290.
41. Ibricevic H, Al-Jame Q. Ferric sulphate and formocresol in pulpotomy of primary molars: long term follow-up study. *Eur J Paediatr Dent.* 2003 Mar;4(1):28-32. PMID: 12870985.
42. Fuks A.B., Holan G., Davis J.M., Eidelman E. Ferric sulfate versus dilute formocresol in pulpotomized primary molars: Long-term follow up. *Pediatr. Dent.* 1997;19:327-330.
43. Ozmen B., Bayrak S. Comparative evaluation of ankaferd blood stopper, ferric sulfate, and formocresol as pulpotomy agent in primary teeth: A clinical study. *Niger J. Clin. Pract.* 2017;20:832-838. doi: 10.4103/1119-3077.197022.